Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...

(Reuters) -Drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Thursday, boosted by cost-cutting, a ...

Pfizer shares rose early Tuesday due to higher than expected demand for its COVID vaccine, but quickly sunk 2.3% after ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...

Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement ...

Pfizer ( PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...

Unexpected demand for Pfizer Inc.’s Covid vaccine helped the company beat quarterly expectations. Then Robert F. Kennedy Jr., ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as ...